Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: Implications for prostate cancer chemoprevention

Journal of Pineal Research

Volumn 42, Issue 2, 2007, Pages 191-202

  Tam, Chun W ^b   Mo, Chi W ^b   Yao, Kwok Ming ^b   Shiu, Stephen Y W ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Androgen; Chemoprevention; Melatonin; p27Kip1; Prostate specific antigen; Protein kinase A; Protein kinase C

Indexed keywords

2 IODOMELATONIN; 4 PHENYL 2 PROPIONAMIDOTETRALINE; ANDROGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PROTEIN KINASE C; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MOLECULAR DYNAMICS; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; GROWTH INHIBITORS; HUMANS; MALE; MELATONIN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33846932844     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2006.00406.x     Document Type: Article

References (47)

1. JEMAL A, THOMAS A, MURRAY T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47 (Errata, CA Cancer J Clin 2002;52:119, 181-182).
2. MIYAMOTO H, MESSING EM, CHANG C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61:332-353.
3. REITER RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49:654-664.
4. REITER RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37:213-214.
5. REITER RJ, GULTEKIN F, MANCHESTER LC et al. Light pollution, melatonin suppression and cancer growth. J Pineal Res 2006; 40:357-358.
6. PRENER A, STORM HH, NIELSEN NH. Cancer of the male genital tract in circumpolar Inuit. Acta Oncol 1996; 35:589-593.
7. DEWAILLY E, MULVAD G, PEDERSEN HS et al. Inuit are protected against prostate cancer. Cancer Epidemiol Biomark Prev 2003; 12:926-927.
8. FEYCHTING M, ÖSTERLUND B, AHLBOM A. Reduced cancer incidence among the blind. Epidemiology 1998; 9:490-494.
9. PUKKALA E, OJAMO M, RUDANKO SL et al. Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment. Cancer Causes Control 2006; 17:573-576.
10. IGUCHI H, KATO KI, IBAYASHI H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55:27-29.
11. SACK RL, LEWY AJ, ERB DL et al. Human melatonin production decreases with age. J Pineal Res 1986; 3:379-388.
12. WALDHAUSER F, WEISZENBACHER G, TATZER E et al. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988; 66:648-652.
13. ZHAO ZY, XIE Y, FU YR et al. Aging and the circadian rhythm of melatonin; a cross-sectional study of Chinese subjects 30-110 yr of age. Chronobiol Int 2002; 19:1171-1182.
14. BARTSCH C, BARTSCH H, SCHMIDT A et al. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients; evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992; 209:153-167.
15. 1 receptor and attenuated sex-steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res 2000; 29:172-183.
16. 1 receptor protein expression. Prostate 2001; 46:52-61.
17. SIU SWF, LAU KW, TAM PC et al. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002; 52:106-122 (Erratum, Prostate 2002;52:252).
18. LUPOWITZ Z, ZISAPEL N. Hormonal interactions in human prostate tumor LNCaP cells. J Steroid Biochem Mol Biol 1999; 68:83-88.
19. MORETTI RM, MARELLI MM, MAGGI R et al. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 2000; 7:347-351.
20. MARELLI MM, LIMONTA P, MAGGI R et al. Growth-inhibitory activity of melatonin on human androgen-independent DU145 prostate cancer cells. Prostate 2000; 45:238-244.
21. SAINZ RM, MAYO JC, TAN DX et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005; 63:29-43.
22. 1 receptor subtype. J Pineal Res 2003; 35:177-182.
23. SRAMKOSKI RM, PRETLOW TG, II, GIACONIA JM et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35:403-409.
24. REPPERT SM, WEAVER DR, GODSON C. Melatonin receptors step into the light; cloning and classification of subtypes. Trends Pharmacol Sci 1996; 17:100-102.
25. PEREZ-STABLE CM, POZAS A, ROOS BA. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol Cell Endocrinol 2000; 167:43-53.
26. KIP1 mRNA levels in tumours of primary and secondary hyperparathyroidism. Clin Endocrinol (Oxf) 2004; 60:389-393.
27. kip1 deregulation in cancer: down regulation or mislocalization. Cell Cycle 2002; 1:394-400.
28. NAVARRO D, LUZARDO OP, FERNÁNDEZ L et al. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002; 81:191-201.
29. BLASK DE, WILSON ST, ZALATAN F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res 1997; 57:1909-1914.
30. SÁNCHEZ-BARCELÓ EJ, COS S, FERNANDEZ R et al. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 2003; 10:153-159.
31. RIMLER A, CULIG Z, LEVY RIMLER G et al. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate 2001; 49:145-154.
32. BLASK DE, SAUER LA, DAUCHY RT et al. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999; 59:4693-4701.
33. MARTÍN V, HERRERA F, CARRERA- GONZALEZ P et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006; 66:1081-1088.
34. WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999; 65:415-420.
35. kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154:313-323.
36. FERNÁNDEZ PL, ARCE Y, FARRÉ X et al. Expression of p27/kip1 is down-regulated in human prostate carcinoma progression. J Pathol 1999; 187:563-566.
37. SUN H, LESCHE R, LI DM et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-triphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1999; 96:6199-6204.
38. Kip1 expression. J Biol Chem 2000; 275:24500-24505.
39. Kip1 is haplo-insufficient for tumor suppression. Nature 1998; 396:177-180.
40. Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995; 55:1211-1214.
41. Kip1 in normal, hyperplastic and neoplastic cells. Am J Pathol 1998; 153:911-919.
42. VIJAYALAXMI, REITER RJ, TAN DX et al. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 2004; 59:639-653.
43. MURILLO H, HUANG H, SCHMIDT LJ et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142:4795-4805.
44. Kip1 promoter transactivation. Mol Cancer Res 2005; 3:163-169.
45. ANDREWS PE, YOUNG CYF, MONTGOMERY BT et al. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic cell line. Cancer Res 1992; 52:1525-1529.
46. LUPOWITZ Z, RIMLER A, ZISAPEL N. Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin. Cell Mol Life Sci 2001; 58:2129-2135.
47. REPPERT SM, WEAVER DR. Melatonin madness. Cell 1995; 83:1059-1062.